A lung cancer diagnostic test is a medical procedure that is used to detect the presence of cancer cells in the lungs. These tests include imaging techniques (such as X-ray and CT scan), tissue biopsy, spit cytology, and advanced methods such as liquid biopsy and molecular tests to identify the type and phase of cancer. The growth of lung cancer diagnostic test market is inspired by increasing demand for personalized treatment based on the government’s initiative for cancer screening and genetic profiling.
Key Growth Drivers and Opportunities
Rising Demand for Personalized Treatment: Increasing demand for personal treatment is significantly increasing the development of lung cancer diagnostic test market, as it requires accurate and wide diagnostic equipment to identify specific genetic mutations, biomarkers and cancer sub-types. Personal remedies, such as targeted drugs and immunotherapy, have greatly rely on accurate clinical consequences for tailor treatment schemes for individual patients. This has increased adopting advanced clinical techniques such as liquid biopsy, next generation sequencing (NGS), and molecular testing. Since healthcare provider and patients want more effective, less aggressive and sewn treatment approaches, the demand for high-collective clinical trials continues to promote market expansion.
Challenges
Lung cancer diagnostic test market faces many borders that can obstruct its growth and access. High costs associated with advanced clinical technologies such as PET scans, liquid biopsy and next generation sequencing make them less cheap in countries with less and moderate income. Additionally, delayed diagnosis in delayed diagnosis due to limited infrastructure, lack of efficient health professionals, and lack of awareness in the reduction of available tests. In some clinical methods, false positive or negative can also cause incorrect diagnosis, affecting the consequences of treatment. Regulatory barriers and variability in testing accuracy further limited widely adopting innovative clinical equipment in clinical settings.
Innovation and Expansion
An Innovative Lung Cancer Screening Trial for High-Risk Individuals has been launched by the EQUAL Study
In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. As lung cancer is becoming more common in younger people and among Asian or Hispanic/Latinx people who have never used tobacco, the team, led by the principal investigator and thoracic oncologist, associate director of Dana-Farber’s Cancer Care Equity Program, designed the study.
Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate.
The LuNGS Alliance has launched a Free NGS Biomarker Screening Program for Lung Cancer
In March 2025, For patients with lung cancer throughout India, the Cancer Research and Statistics Foundation (CRSF)-led LuNGS Alliance has announced free lung NGS biomarker testing. AstraZeneca, Pfizer, and Roche support this program, and 4baseCare is the official lab partner. The initiative’s goal is to raise awareness of precision oncology as a crucial, easily accessible, and reasonably priced therapy option for lung cancer.
4baseCare’s TARGT First Solid test provides a thorough examination of 72 frequently mutated genes, revealing actionable biomarkers that allow for individualized treatment regimens based on each patient’s own genetic profile. The test finds mutations that match FDA and NCCN-approved medications, enabling oncologists to offer more individualized, potent treatments that can greatly enhance patient outcomes.
Inventive Sparks, Expanding Markets
The key players operating in the lung cancer diagnostic test market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
